Wall Street analysts expect Miragen Therapeutics Inc (NASDAQ:MGEN) to post earnings of ($0.37) per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Miragen Therapeutics’ earnings, with estimates ranging from ($0.39) to ($0.35). Miragen Therapeutics posted earnings per share of ($0.29) during the same quarter last year, which indicates a negative year over year growth rate of 27.6%. The firm is scheduled to issue its next earnings results on Tuesday, August 6th.

On average, analysts expect that Miragen Therapeutics will report full-year earnings of ($1.41) per share for the current year, with EPS estimates ranging from ($1.54) to ($1.08). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.43) per share, with EPS estimates ranging from ($1.81) to ($0.89). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Miragen Therapeutics.

Miragen Therapeutics (NASDAQ:MGEN) last posted its quarterly earnings data on Wednesday, May 8th. The medical research company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.03). The company had revenue of $0.37 million during the quarter, compared to analysts’ expectations of $1.35 million. Miragen Therapeutics had a negative return on equity of 71.91% and a negative net margin of 998.26%.

A number of equities research analysts have issued reports on the company. Zacks Investment Research upgraded General Moly from a “sell” rating to a “hold” rating in a research note on Thursday, July 11th. ValuEngine lowered Zosano Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. Finally, Wedbush reiterated a “buy” rating and issued a $24.00 price target on shares of Miragen Therapeutics in a research note on Tuesday, May 21st. One analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $16.00.

MGEN stock traded down $0.08 during trading on Monday, reaching $2.25. The company’s stock had a trading volume of 81,266 shares, compared to its average volume of 236,115. Miragen Therapeutics has a 1 year low of $2.01 and a 1 year high of $7.07. The company has a quick ratio of 7.90, a current ratio of 7.90 and a debt-to-equity ratio of 0.17. The firm has a market cap of $72.07 million, a P/E ratio of -2.05 and a beta of 1.15. The company has a fifty day moving average price of $2.28.

A number of hedge funds have recently modified their holdings of MGEN. Rhumbline Advisers increased its stake in Miragen Therapeutics by 51.4% in the 4th quarter. Rhumbline Advisers now owns 33,350 shares of the medical research company’s stock worth $101,000 after buying an additional 11,321 shares in the last quarter. BlackRock Inc. increased its stake in Miragen Therapeutics by 3.4% in the 4th quarter. BlackRock Inc. now owns 1,459,881 shares of the medical research company’s stock worth $4,423,000 after buying an additional 48,128 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Miragen Therapeutics by 59.1% during the fourth quarter. Bank of New York Mellon Corp now owns 99,844 shares of the medical research company’s stock valued at $302,000 after purchasing an additional 37,101 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Miragen Therapeutics by 2.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 216,866 shares of the medical research company’s stock valued at $657,000 after purchasing an additional 4,404 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Miragen Therapeutics by 5.3% during the fourth quarter. Geode Capital Management LLC now owns 230,127 shares of the medical research company’s stock valued at $697,000 after purchasing an additional 11,541 shares in the last quarter. Institutional investors and hedge funds own 42.81% of the company’s stock.

About Miragen Therapeutics

Miragen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous, ocular, and idiopathic pulmonary fibrosis; and MRG-110, an inhibitor of miR-92, a microRNA expressed in endothelial cells for the treatment of heart failure, as well as surgical incisions in high risk populations, severe lacerations, and severe burns in the United States and Japan.

Featured Story: Net Income

Get a free copy of the Zacks research report on Miragen Therapeutics (MGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Miragen Therapeutics (NASDAQ:MGEN)

Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.